MAP4K1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL852827	0.32	13/20
SCHEMBL112088	0.51	11/20
SCHEMBL721560	0.59	7/20
SCHEMBL520502	0.47	7/20
SCHEMBL112357	0.44	7/20
SCHEMBL722011	0.56	5/20
SCHEMBL670900	0.50	5/20
SCHEMBL533183	0.48	5/20
SCHEMBL527037	0.39	5/20
SCHEMBL182816	0.61	4/20
SCHEMBL182950	0.60	4/20
SCHEMBL553809	0.56	4/20
SCHEMBL473670	0.44	4/20
SCHEMBL400213	0.39	4/20
SCHEMBL467747	0.38	4/20
SCHEMBL245459	0.31	4/20
SCHEMBL723387	0.67	3/20
SCHEMBL560197	0.52	3/20
SCHEMBL147381	0.50	3/20
SCHEMBL520622	0.50	3/20

Clinical trials — most relevant to MAP4K1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...	PHASE2	COMPLETED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	PHASE2	RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	PHASE1/PHASE2	RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer	PHASE2	COMPLETED
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery	PHASE2	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Glutamate Supplementation in Young Men	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP4K1 binder may also engage these)

Protein	Name	Similarity
P70218	—	1.000	P70218 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.995	landscape →
Q61161	—	0.991	Q61161 →
Q9Y613	—	0.984	Q9Y613 →
Q9UJY4	—	0.983	Q9UJY4 →
E6ZIJ1	—	0.982	E6ZIJ1 →
Q9BST9	—	0.981	Q9BST9 →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.981	landscape →
Q32P44	—	0.981	Q32P44 →
Q9ESJ4	—	0.981	Q9ESJ4 →
Q8VC03	—	0.981	Q8VC03 →
P51432	—	0.981	P51432 →
Q99ML2	—	0.981	Q99ML2 →
Q60875	—	0.981	Q60875 →
Q9R011	—	0.981	Q9R011 →
Q5RJI5	—	0.980	Q5RJI5 →
Q4ACU6	—	0.980	Q4ACU6 →
Q8BMI3	—	0.980	Q8BMI3 →
GRB7	Growth factor receptor-bound protein 7	0.980	landscape →
Q0QWG9	—	0.980	Q0QWG9 →
B2DD29	—	0.979	B2DD29 →
Q8C6B2	—	0.979	Q8C6B2 →
Q8R5F8	—	0.979	Q8R5F8 →
Q5FVC2	—	0.979	Q5FVC2 →
Q96P48	—	0.979	Q96P48 →
Q9UJY5	—	0.979	Q9UJY5 →
Q9WTR2	—	0.979	Q9WTR2 →
Q9BYB0	—	0.979	Q9BYB0 →
Q3TJ91	—	0.979	Q3TJ91 →
RNF31	E3 ubiquitin-protein ligase RNF31	0.978	landscape →